Syngene has released its Investor Presentation for the quarter and half-year ended September 30, 2026. The document details key operating highlights, including advancements in Integrated Drug Discovery, Bayview Biologics Facility, and Biologics Manufacturing. Financial highlights for Q2 FY27 and H1 FY27 are provided, alongside an overview of the company’s strengths, growth strategy, and commitment to sustainability.
Syngene Investor Presentation for Q2 FY27 Disclosed
Syngene International Limited has submitted its Investor Presentation for the quarter and half-year ended September 30, 2026. This presentation will be utilized in upcoming meetings with analysts and institutional investors, and is also available on the company’s website.
Q2 FY27 Performance Highlights
Operating Highlights
- Integrated Drug Discovery (IDD): Syngene has strengthened its IDD offering by unifying Chemistry, Biology, and Biotherapeutics under the Chief Scientific Officer.
- Bayview Biologics Facility: A significant manufacturing agreement was signed for the Bayview facility, marking a milestone in large-molecule manufacturing. Process development is underway in India, with drug-substance manufacturing planned in Bayview next year.
- Biologics Manufacturing: Additional manufacturing contracts have been secured, including an agreement to supply clinical materials from the Bengaluru biologics facility, indicating strong customer traction.
- Capability Enhancement: A Clinical Translational Sciences laboratory was commissioned in Bengaluru, integrating various clinical capabilities. Digital capabilities have also been expanded.
- Cost Competitiveness: Ongoing cost-optimization initiatives aim to improve operational efficiency and competitiveness.
Q2 FY27 Financial Highlights
- Revenue from Operations: Rs 833 Cr (+13% QoQ, -9% YoY)
- Operating EBITDA margin: 18% (12% in Q1FY27, 22% in Q2 FY26)
- PAT, before exceptional items: Rs 38 Cr (Rs. 1 Cr in Q1FY27, Rs. 67 Cr in Q2FY26)
- PAT, after exceptional items: Rs 32 Cr (Rs. 9 Cr Loss in Q1FY27, Rs. 67 Cr in Q2FY26)
Company Overview and Strategy
The presentation also covers Syngene’s identity as a world-class partner in innovation, offering integrated solutions across research, development, and manufacturing. Its sector expertise spans pharmaceuticals, biotech, nutrition, animal health, consumer goods, and specialty chemicals. The company boasts a significant team of over ~5,700 scientists operating across four global campuses and has an established track record in discovery research and development/manufacturing for both small and large molecules.
Syngene’s journey highlights significant growth and expansion, including globalization and strategic collaborations. The company’s 3-pronged growth strategy focuses on Research Services, Development and Manufacturing for Large Molecules, and Development and Manufacturing Services for Small Molecules. This is complemented by a focus on Operational Excellence, People development, and Environmental, Social, and Governance (ESG) commitments.
Syngene Strengths and Infrastructure
Key strengths include being a global scale CRDMO player, solutions through innovation with IP assignment to clients, and high-quality standards with a fully digitized quality organization and strong compliance track record. The company emphasizes its science in its DNA, with a global presence and a substantial R&D and manufacturing infrastructure.
The company has extended its state-of-the-art infrastructure with a global presence, including its HQ campus in Bangalore, India, an R&D Centre in Hyderabad, India, and a Biologics facility in Baltimore, USA, alongside API manufacturing in Mangalore, India.
Financials and Shareholding
Detailed financial highlights for Q2 FY27 and FY26 are provided, showing revenue from operations, EBITDA, and PAT. Balance Sheet highlights as of September 30, 2026, indicate Shareholders’ funds of Rs 4,859 Cr.
Syngene’s shareholding structure shows 53% Promoter & Promoter Group, 47% Public, and 0.4% ESOP Trust as of September 30, 2026. Share information includes NSE Ticker: SYNGENE, BSE Ticker: 539268, and Market Cap (Rs. Cr): 14,382.
Safety and Sustainability Commitments
Syngene is committed to safety, holding ISO 45001:2018 accreditation, and prioritizes risk assessments and employee safety programs. The company is also dedicated to environmental protection, having achieved significant reductions in emissions and high procurement of energy from renewable sources. ESG rating performance across various agencies demonstrates a strong commitment to sustainable growth.
Source: BSE
